A Design of Experiments‐Based Chiral HPLC Method for the Quantification of Talazoparib and Enantiomeric Purity Determination in Pharmaceutical Formulations
Open Access
Abstract
Talazoparib is an oral inhibitor of the polyadenosine 5′‐diphosphoribose polymerase enzymes used for the treatment of adults with deleterious or suspected deleterious germline BRCA ‐mutated, human epidermal growth factor receptor 2‐negative, locally advanced, or metastatic breast cancer. A novel chiral HPLC method was proposed for the enantiomeric separation and quantification of talazoparib. Chiral separation was performed in a reversed‐phase mode on a Chiralpak IC (4.6 × 250 mm, 5 μm) column using a simple mobile phase consisting of 0.2% perchloric acid in water:acetonitrile (60:40, v/v). A Box–Behnken design was used for the optimization of chromatographic parameters, and the enantiomeric separation was obtained within 12 min with a resolution value exceeding 7.7. The method was validated with respect to specificity, linearity, accuracy, precision, and robustness. The accuracy and precision of the method were satisfactory, with intraday and interday recovery values of 98%–102% and relative standard deviation values less than 2%. The method was used for the enantiomeric purity control of talazoparib in pharmaceutical formulations, which is crucial for patient safety and therapeutic efficacy.Keywords
Funding Information
- Anadolu Üniversitesi (BGT‐2024‐2392)
This publication has 23 references indexed in Scilit:
- Talazoparib: First Global ApprovalDrugs, 2018
- A new tool for the evaluation of the analytical procedure: Green Analytical Procedure IndexTalanta, 2018
- Development and validation of a high‐performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studiesBiomedical Chromatography, 2017
- Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer AgentJournal of Medicinal Chemistry, 2015
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and RucaparibMolecular Cancer Therapeutics, 2014
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair DeficiencyClinical Cancer Research, 2013
- Recent developments on polysaccharide-based chiral stationary phases for liquid-phase separation of enantiomersJournal of Chromatography A, 2012
- Chiral Separation by HPLC Using Polysaccharide-Based Chiral Stationary Phases2003
- Applications of Polysaccharide-Based Chiral Stationary Phases for Resolution of Different Compound Classes2003
- Reversed-phase liquid chromatographic separation of enantiomers on polysaccharide type chiral stationary phasesJournal of Chromatography A, 2001